Another study showed that the combination of mTOR inhibitor with 5-FU, oxaliplatin and SN38 in colorectal cancer cell lines had synergistic effect only in the cell lines which contained a PI3K or P53 mutation with wide-type KRAS. Here, KRAS is linked to colorectal cancer.